Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. West Pharmaceutical Services's current 3-Year Share Buyback Ratio was 0.90%.
The historical rank and industry rank for West Pharmaceutical Services's 3-Year Share Buyback Ratio or its related term are showing as below:
WST'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3 Med: -0.5 Max: 4.8
Current: 0.9
During the past 13 years, West Pharmaceutical Services's highest 3-Year Share Buyback Ratio was 4.80%. The lowest was -4.30%. And the median was -0.50%.
WST's 3-Year Share Buyback Ratio is ranked better than 91.35% of 613
companies
in the Medical Devices & Instruments industry
Industry Median: -2.6
vs WST: 0.90
West Pharmaceutical Services (NYSE:WST) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
West Pharmaceutical Services 3-Year Share Buyback Ratio Related Terms
WST vs RMD, COO, SOLV: 3-Year Share Buyback Ratio Comparison
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's 3-Year Share Buyback Ratio falls into.
West Pharmaceutical Services 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.90 mean?
West Pharmaceutical Services (WST) has a 3-Year Share Buyback Ratio of 0.90 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for West Pharmaceutical Services and its competitors. According to the industry distribution chart, West Pharmaceutical Services ranks #53 out of 613 companies in the Medical Devices & Instruments industry, placing it in the top 8.6%.
Is West Pharmaceutical Services' 3-Year Share Buyback Ratio too high?
West Pharmaceutical Services' current 3-Year Share Buyback Ratio is 0.90. Based on the distribution chart, West Pharmaceutical Services ranks #53 out of 613 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, West Pharmaceutical Services has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' 3-Year Share Buyback Ratio compare to RMD and COO?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #53 out of 613 companies for 3-Year Share Buyback Ratio. This places West Pharmaceutical Services in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for West Pharmaceutical Services and its competitors. West Pharmaceutical Services's current 3-Year Share Buyback Ratio is 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $356.64, compared to a current price of $354.07 — trading 0.7% below its estimated fair value. The current 3-Year Share Buyback Ratio is 0.90. West Pharmaceutical Services' overall GF Score™ is 96/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current 3-Year Share Buyback Ratio is 0.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is West Pharmaceutical Services (WST) Overvalued in 2026?
Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued.
The current stock price of $354.07 is trading 0.7% below its estimated GF Value™ of $356.64.
GuruFocus considers West Pharmaceutical Services to be Fairly Valued.
Key valuation signals for WST:
3-Year Share Buyback Ratio: 0.90
GF Value™: $356.64 vs. price of $354.07 (0.7% below fair value)
No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
96GF Score
Get the complete analysis for WST
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WST has been successfully added to your 
